Search Results 971-980 of 17075 for monoclonal antibody

1. A Study to Evaluate the Effectiveness and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma - Mayo Clinic

   Monoclonal antibody, at least 3 half-lives from last dose;; Non-antibody immunotherapy (e.g., tumor vaccine), at least 42 days from last dose ...

2. A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS) - Mayo Clinic

   History of severe hypersensitivity reaction to any monoclonal antibody. Other severe acute or chronic medical (including bone marrow suppressive diseases) ...

3. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab - Mayo Clinic

   History of severe hypersensitivity reaction to any monoclonal antibody. Women of Childbearing Potential (WOCBP) who are pregnant or breastfeeding. Women ...

4. Advances in lung cancer immunotherapy and management of immune-mediated adverse events - Mayo Clinic

   Monotherapy, using the anti-PD-1 antibody pembrolizumab, is now Food and Drug Administration (FDA) approved for patients with stage IV non-small cell lung ...

5. Stereotactic Radiosurgery Clinical Trials - Mayo Clinic Research

   Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a ...

6. Medical Research & Education - Mayo Clinic News Network

   Is the definition of Alzheimer's disease changing? Dana Sparks. November 6, 2018. Mayo researchers correlate specific antibody with relapse of neurological ...

7. Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy - Mayo Clinic

   Patients who have been treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in any other clinical studies; Pregnant or ...

8. Trial to Assess Safety and Effectiveness of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) - Mayo Clinic

   ... antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory). Participation ...

9. A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis - Mayo Clinic

   Note: Subjects with antibodies to HBsAg ... Hypersensitivity: Subjects with a known allergy or intolerance to a monoclonal antibody or biologic therapy.

10. Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer - Mayo Clinic

    Major surgery, significant trauma, wide-field radiotherapy, or therapy with monoclonal antibodies within 4 weeks before the first dose of study drug ...